 Three dose levels of HBI-8000 15 mg, 20 mg, and 25 mg will be tested using a standard 33 escalation plan with an expanded cohort at the maximum tolerated dose MTD to enroll a minimum of 10 patients evaluable for safety to fulfill the requirements for moving the combination forward to I-SPY 2 trial. 